DongKook Pharmaceutical Co. Ltd (086450) - Net Assets

Latest as of December 2025: ₩763.74 Billion KRW ≈ $517.57 Million USD

Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has net assets worth ₩763.74 Billion KRW (≈ $517.57 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.06 Trillion ≈ $720.31 Million USD) and total liabilities (₩299.16 Billion ≈ $202.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 086450 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩763.74 Billion
% of Total Assets	71.85%
Annual Growth Rate	13.78%
5-Year Change	68.01%
10-Year Change	221.82%
Growth Volatility	3.25

DongKook Pharmaceutical Co. Ltd - Net Assets Trend (2013–2025)

This chart illustrates how DongKook Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore DongKook Pharmaceutical Co. Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for DongKook Pharmaceutical Co. Ltd (2013–2025)

The table below shows the annual net assets of DongKook Pharmaceutical Co. Ltd from 2013 to 2025. For live valuation and market cap data, see market cap of DongKook Pharmaceutical Co. Ltd.

Year	Net Assets	Change
2025-12-31	₩763.74 Billion ≈ $517.57 Million	+12.48%
2024-12-31	₩678.98 Billion ≈ $460.13 Million	+17.84%
2023-12-31	₩576.17 Billion ≈ $390.46 Million	+14.79%
2022-12-31	₩501.94 Billion ≈ $340.16 Million	+10.42%
2021-12-31	₩454.57 Billion ≈ $308.05 Million	+10.50%
2020-12-31	₩411.37 Billion ≈ $278.78 Million	+13.36%
2019-12-31	₩362.87 Billion ≈ $245.91 Million	+15.93%
2018-12-31	₩313.02 Billion ≈ $212.13 Million	+18.60%
2017-12-31	₩263.94 Billion ≈ $178.87 Million	+11.22%
2016-12-31	₩237.32 Billion ≈ $160.83 Million	+18.89%
2015-12-31	₩199.62 Billion ≈ $135.28 Million	+13.06%
2014-12-31	₩176.57 Billion ≈ $119.66 Million	+8.83%
2013-12-31	₩162.24 Billion ≈ $109.95 Million	--

Equity Component Analysis

This analysis shows how different components contribute to DongKook Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 61297035691000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩612.97 Billion	92.35%
Other Components	₩50.77 Billion	7.65%
Total Equity	₩663.74 Billion	100.00%

DongKook Pharmaceutical Co. Ltd Competitors by Market Cap

The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their market capitalization.

Company	Market Cap
Leifheit Aktiengesellschaft F:LEI	$142.42 Million
Limes Schlosskliniken AG XETRA:LIK	$142.49 Million
Oncolytics Biotech Inc TO:ONC	$142.51 Million
Excelliance MOS TWO:5299	$142.53 Million
PT Satu Visi Putra Tbk JK:VISI	$142.34 Million
Casa de Bolsa Finamex S.A.B. de C.V MX:FINAMEXO	$142.27 Million
Dynagas LNG Partners LP NYSE:DLNG	$142.25 Million
Alan Allman Associates SA PA:AAA	$142.19 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in DongKook Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 603,477,008,790 to 663,741,382,110, a change of 60,264,373,320 (10.0%).
Net income of 66,020,354,860 contributed positively to equity growth.
Dividend payments of 9,243,589,280 reduced retained earnings.
New share issuances of 18,540,000,000 increased equity.
Other factors decreased equity by 15,052,392,260.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩66.02 Billion	+9.95%
Dividends Paid	₩9.24 Billion	-1.39%
Share Issuances	₩18.54 Billion	+2.79%
Other Changes	₩-15.05 Billion	-2.27%
Total Change	₩-	9.99%

Book Value vs Market Value Analysis

This analysis compares DongKook Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.60x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 4.43x to 1.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩5399.87	₩23900.00	x
2017-12-31	₩6005.66	₩23900.00	x
2018-12-31	₩7122.52	₩23900.00	x
2019-12-31	₩8256.85	₩23900.00	x
2020-12-31	₩9360.27	₩23900.00	x
2021-12-31	₩10343.19	₩23900.00	x
2022-12-31	₩11419.31	₩23900.00	x
2023-12-31	₩12390.02	₩23900.00	x
2024-12-31	₩13725.27	₩23900.00	x
2025-12-31	₩14951.81	₩23900.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently DongKook Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.95%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.12%
• Asset Turnover: 0.87x
• Equity Multiplier: 1.60x
Recent ROE (9.95%) is below the historical average (12.51%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	10.36%	7.87%	0.98x	1.35x	₩575.42 Million
2014	11.97%	9.33%	0.93x	1.38x	₩3.47 Billion
2015	13.74%	10.55%	0.95x	1.38x	₩7.46 Billion
2016	17.13%	13.13%	0.95x	1.37x	₩16.93 Billion
2017	15.00%	11.16%	0.95x	1.41x	₩13.21 Billion
2018	15.00%	11.71%	0.83x	1.53x	₩15.65 Billion
2019	15.52%	11.68%	0.89x	1.50x	₩20.02 Billion
2020	13.59%	10.00%	0.84x	1.61x	₩14.79 Billion
2021	11.08%	8.47%	0.79x	1.65x	₩4.89 Billion
2022	10.54%	7.99%	0.86x	1.53x	₩2.70 Billion
2023	8.66%	6.45%	0.87x	1.54x	₩-7.29 Billion
2024	10.14%	7.54%	0.85x	1.58x	₩871.25 Million
2025	9.95%	7.12%	0.87x	1.60x	₩-353.78 Million

Industry Comparison

This section compares DongKook Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $93,324,927,632
Average return on equity (ROE) among peers: 5.93%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
DongKook Pharmaceutical Co. Ltd (086450)	₩763.74 Billion	10.36%	0.39x	$142.36 Million
Sam Chun Dang Pharm. Co. Ltd (000250)	$186.63 Billion	-0.52%	0.70x	$6.03 Billion
DongKoo Bio&Pharma Co. Ltd (006620)	$102.11 Billion	6.48%	0.69x	$33.52 Million
NatureCell Co.Ltd (007390)	$13.75 Billion	13.78%	0.78x	$688.81 Million
Sam-A Pharm. Co. Ltd (009300)	$148.92 Billion	6.63%	0.09x	$68.66 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$220.06 Billion	2.49%	0.38x	$89.89 Million
WooGene B&G Co. Ltd (018620)	$29.85 Billion	-6.92%	1.60x	$13.13 Million
Oscotec Inc (039200)	$46.29 Billion	7.50%	0.52x	$990.30 Million
EstechPharma Co. Ltd (041910)	$82.38 Billion	3.31%	0.15x	$59.21 Million
Komipharm International Co. Ltd (041960)	$65.54 Billion	20.01%	0.87x	$380.81 Million
Eagle Veterinary Technology Co.Ltd (044960)	$37.74 Billion	6.52%	0.28x	$34.35 Million

About DongKook Pharmaceutical Co. Ltd

KQ:086450 Korea Pharmaceuticals

Market Cap

$142.36 Million

₩210.07 Billion KRW

Market Cap Rank

#17833 Global

#861 in Korea

Share Price

₩23900.00

Change (1 day)

-2.85%

52-Week Range

₩15240.00 - ₩29900.00

All Time High

₩31498.93